Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia

Leukemia and Lymphoma

Volumn 51, Issue 2, 2010, Pages 275-278

  Carella, Angelo M ^a   Garuti, Anna ^a   Cirmena, Gabriella ^a   Catania, Gioacchino ^a   Rocco, Ilaria ^a   Palermo, Claudia ^a   Pica, Gianmatteo ^a   Pierri, Ivana ^a   Miglino, Maurizio ^a   Ballestrero, Alberto ^a   Gobbi, Marco ^a   Patrone, Franco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Chronic myeloid leukemia; Disease progression; Kinase domain mutations at diagnosis

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ARTICLE; CANCER GROWTH; CANCER RISK; CAPILLARY ELECTROPHORESIS; CHRONIC MYELOID LEUKEMIA; CHRONICITY; GENE MUTATION; GENE SEQUENCE; HIGH RISK PATIENT; LEUKEMIA REMISSION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; MUTATION; OUTCOME ASSESSMENT (HEALTH CARE); PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; YOUNG ADULT;

EID: 76349107156     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903503446     Document Type: Article

References (19)

1. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
2. Druker B, Guilhot F, O'Brien S, et al. Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival. N Engl J Med 2006;355:2408-2417.
3. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
4. Kantarjian HM, Cortes JE, O'Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 2004;104: 1979-1988.
5. Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment. Blood 2008;111:1039-1043.
6. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-1029.
7. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880.
8. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-2653.
9. Corbin AS, La Rosee P, Stroffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003;101:4611-4614.
10. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-4505.
11. Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100-4109.
12. Branford S, Cross NCP, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006;20:1925-1930.
13. Hughes TP, Deininger MW, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37.
14. Baccarani M, Martinelli G, Rosti G, et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukaemia. Blood 2004;104: 4245-4251.
15. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008;112:3330-3338.
16. Deininger M. Milestones and monitoring in patients with CML treated with imatinib. Hematology 2008;418-426.
17. Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL). Blood 2007;110:727-734.
18. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukaemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3308-3309.
19. Kantarjian H, Quintas-Cardama A, O'Brien S, et al. Importance of early intervention with dasatinib at cytogenetic rather than hematologic resistance to imatinib. Blood 2007;110:314a.